J&J’s talc litigation persists, business strength and financial flexibility soften impact - Moody’s
J&J revealed that its proposed prepackaged bankruptcy plan for Red River Talc LLC was not approved by the U.S. Bankruptcy Court for the Southern District of Texas. Instead of appealing, J&J plans to ...
Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...
PMLive2d
Johnson & Johnson’s Tremfya recommended by CHMP to treat Crohn’s disease
Johnson & Johnson (J&J) has announced that its Tremfya (guselkumab) has been recommended by the European Medicines Agency’s ...
MPR5d
MPR Weekly Dose Podcast #230
New antibiotic has been approved for uncomplicated UTIs; Cabometyx approved for advanced neuroendocrine tumors; new rosacea treatment option; Tremfya ...
Rheumatology Advisor5d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
Johnson & Johnson (NYSE:JNJ) Presents Promising Nipocalimab Data At AAN Annual Meeting
Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several ...
Pharmaceutical Technology6d
AGA overhauls UC treatment pathway: early, high-efficacy therapies now preferred
In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...